Cargando…
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335792/ https://www.ncbi.nlm.nih.gov/pubmed/37441428 http://dx.doi.org/10.3389/fonc.2023.1236311 |
| _version_ | 1785071071253233664 |
|---|---|
| author | Fu, Yulong Wang, Anqi Zhou, Jieqi Feng, Wei Shi, Minhua Xu, Xiao Zhao, Hongqing Cai, Liming Feng, Jian Lv, Xuedong Zhang, Xiaodong Xu, Wenjing Zhang, Zhengrong Ma, Guoer Wang, Jian Zhou, Tong Zhao, Dahai Fang, Haohui Liu, Zeyi Huang, Jian-an |
| author_facet | Fu, Yulong Wang, Anqi Zhou, Jieqi Feng, Wei Shi, Minhua Xu, Xiao Zhao, Hongqing Cai, Liming Feng, Jian Lv, Xuedong Zhang, Xiaodong Xu, Wenjing Zhang, Zhengrong Ma, Guoer Wang, Jian Zhou, Tong Zhao, Dahai Fang, Haohui Liu, Zeyi Huang, Jian-an |
| author_sort | Fu, Yulong |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10335792 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103357922023-07-12 Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy Fu, Yulong Wang, Anqi Zhou, Jieqi Feng, Wei Shi, Minhua Xu, Xiao Zhao, Hongqing Cai, Liming Feng, Jian Lv, Xuedong Zhang, Xiaodong Xu, Wenjing Zhang, Zhengrong Ma, Guoer Wang, Jian Zhou, Tong Zhao, Dahai Fang, Haohui Liu, Zeyi Huang, Jian-an Front Oncol Oncology Frontiers Media S.A. 2023-06-27 /pmc/articles/PMC10335792/ /pubmed/37441428 http://dx.doi.org/10.3389/fonc.2023.1236311 Text en Copyright © 2023 Fu, Wang, Zhou, Feng, Shi, Xu, Zhao, Cai, Feng, Lv, Zhang, Xu, Zhang, Ma, Wang, Zhou, Zhao, Fang, Liu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Fu, Yulong Wang, Anqi Zhou, Jieqi Feng, Wei Shi, Minhua Xu, Xiao Zhao, Hongqing Cai, Liming Feng, Jian Lv, Xuedong Zhang, Xiaodong Xu, Wenjing Zhang, Zhengrong Ma, Guoer Wang, Jian Zhou, Tong Zhao, Dahai Fang, Haohui Liu, Zeyi Huang, Jian-an Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy |
| title | Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy |
| title_full | Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy |
| title_fullStr | Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy |
| title_full_unstemmed | Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy |
| title_short | Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy |
| title_sort | corrigendum: advanced nsclc patients with egfr t790m harbouring tp53 r273c or kras g12v cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335792/ https://www.ncbi.nlm.nih.gov/pubmed/37441428 http://dx.doi.org/10.3389/fonc.2023.1236311 |
| work_keys_str_mv | AT fuyulong corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT wanganqi corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT zhoujieqi corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT fengwei corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT shiminhua corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT xuxiao corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT zhaohongqing corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT cailiming corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT fengjian corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT lvxuedong corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT zhangxiaodong corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT xuwenjing corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT zhangzhengrong corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT maguoer corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT wangjian corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT zhoutong corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT zhaodahai corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT fanghaohui corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT liuzeyi corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy AT huangjianan corrigendumadvancednsclcpatientswithegfrt790mharbouringtp53r273corkrasg12vcannotbenefitfromosimertinibbasedonaclinicalmulticentrestudybytissueandliquidbiopsy |